<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30170">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01998217</url>
  </required_header>
  <id_info>
    <org_study_id>Rem-ESWL-Pancreas</org_study_id>
    <nct_id>NCT01998217</nct_id>
  </id_info>
  <brief_title>Combination of Remifentanil and Flurbiprofen in Sedation and Analgesia for ESWL of Pancreatic Stone</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extracorporeal shock wave lithotripsy (ESWL) of pancreatic stones has been described as an
      effective approach for stone drainage and pain relief, and general or epidural anesthesia
      has been reported for such procedure. Single infusion of remifentanil has been described in
      ESWL of urinary stones, but it has never been described in ESWL of pancreatic stones.
      Moreover, single infusion of remifentanil might induce several complications, such as
      postoperative nausea and vomiting. The investigators attended to investigated whether
      combination of flurbiprofen with remifentanil reduced remifentanil dose and attenuated the
      complications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Visual analogue score of pain</measure>
    <time_frame>During ESWL procedure</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular responses including blood pressure and heart rate</measure>
    <time_frame>During ESWL procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Side effects</measure>
    <time_frame>within 24 hours after ESWL procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>The side effects including postoperative nausea and vomiting, as well as pruritus.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pancreatic Stone Disease</condition>
  <arm_group>
    <arm_group_label>Rem group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group receive single infusion of remifentanil with target concentration infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flur group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group receive both infusion of flurbiprofen and remifentanil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Patients in Rem group receive sedation and analgesia with remifentanil, dose of which will be determined by the up-and-down method.</description>
    <arm_group_label>Rem group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flurbiprofen and remifentanil</intervention_name>
    <description>Patients in this group receive sedation and analgesia with flurbiprofen and remifentanil, dose of which was determined by the up-and-down method.</description>
    <arm_group_label>Flur group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 18-65 years

          -  ASA I-II

          -  ESWL indication was met

        Exclusion Criteria:

          -  patients with hypertension

          -  patients compromised in cardiopulmonary function

          -  patients undergoing ESWL for the second or more times
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jia-feng Wang, M.D.</last_name>
    <phone>+86-21-31161853</phone>
    <email>feng_smmu@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Anesthesiology, Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia-feng Wang, M.D.</last_name>
      <phone>+86-21-31161853</phone>
      <email>feng_smmu@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jia-feng Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 23, 2013</lastchanged_date>
  <firstreceived_date>November 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Jia-feng Wang</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>extracorporeal shock wave lithotripsy</keyword>
  <keyword>remifentanil</keyword>
  <keyword>flurbiprofen</keyword>
  <keyword>pancreatic stone</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calculi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Flurbiprofen</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
